EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
248.37M
Enterprise Value 3
153.31M
Trailing P/E
N/A
Forward P/E 1
-5.38
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
2.82
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-2.29

Trading Information

Stock Price History

Beta (3Y Monthly) 0.31
52-Week Change 3-0.59%
S&P500 52-Week Change 37.98%
52 Week High 315.33
52 Week Low 38.40
50-Day Moving Average 310.80
200-Day Moving Average 311.14

Share Statistics

Avg Vol (3 month) 3114.62k
Avg Vol (10 day) 361.38k
Shares Outstanding 524.45M
Float 16.58M
% Held by Insiders 11.88%
% Held by Institutions 181.31%
Shares Short (Sep 30, 2019) 4773.22k
Short Ratio (Sep 30, 2019) 45.49
Short % of Float (Sep 30, 2019) 44.68%
Short % of Shares Outstanding (Sep 30, 2019) 43.16%
Shares Short (prior month Aug 30, 2019) 4676.44k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 215/1
Last Split Date 3Mar 23, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-40.22%
Return on Equity (ttm)-99.54%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -66.96M
Net Income Avi to Common (ttm)-68.36M
Diluted EPS (ttm)-3.65
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)125.33M
Total Cash Per Share (mrq)5.13
Total Debt (mrq)31.98M
Total Debt/Equity (mrq)36.31
Current Ratio (mrq)9.64
Book Value Per Share (mrq)3.60

Cash Flow Statement

Operating Cash Flow (ttm)-60.26M
Levered Free Cash Flow (ttm)-32.6M